Is there a GLP-1 made for menopause weight gain?

No. GLP-1 drugs are approved by BMI, not menopausal status, and no menopause-specific trial establishes a different effect. Wegovy and Zepbound are the weight-approved options a midlife woman would qualify for on the same criteria as anyone else.

Will a GLP-1 cause muscle loss in menopause?

Any large weight loss includes some lean-mass loss, and midlife women already face age-related muscle changes. Resistance training and adequate protein are commonly emphasized to help preserve muscle; discuss bone and muscle health with a clinician.

Does HRT change how a GLP-1 works?

There is no established interaction that changes GLP-1 weight effects, but combining therapies is individual. If you take or are considering hormone therapy, review the full plan with a clinician who can see both treatments together.

By condition and life stage

What Is the Best GLP-1 for Menopause Weight Gain?

Medically reviewed by Editorial Medical Review, MD, NAMS-CMP · Updated July 2026

Quick answer

No GLP-1 is approved specifically for menopause weight gain; approvals are based on BMI, not menopausal status. Semaglutide and tirzepatide are the weight-approved options, and tirzepatide showed the larger average trial weight loss. For midlife women, muscle and bone preservation are the extra considerations a clinician weighs.

Menopause changes body composition

Research from the SWAN study documented that the menopause transition is associated with a shift toward more fat and less lean mass, and a tendency for fat to accumulate around the abdomen. That biology is why midlife weight gain can feel different from earlier-life weight change.

GLP-1 drugs are not approved based on menopausal status, though. Wegovy and Zepbound are approved by BMI thresholds, so a woman qualifies on the same criteria whether or not she is in menopause.

Molecule choice for midlife weight

Tirzepatide produced a larger average weight reduction across its trials (up to about 20.9% in SURMOUNT-1) than semaglutide did in STEP 1 (about 14.9%). No menopause-specific trial establishes a different effect for midlife women, so these general trial figures are the best available reference.

The right choice still depends on tolerability, cost, coverage, and other medications, which is a clinician decision rather than a fixed ranking.

Muscle and bone preservation

Any substantial weight loss includes some loss of lean mass, and midlife women already face age-related muscle and bone changes. This is why resistance training and adequate protein are commonly emphasized alongside GLP-1 treatment, and why bone health is worth discussing with a clinician, especially after menopause.

These are general supportive-care principles, not personalized advice, and they apply on either molecule.

Molecule guide vs provider ranking

This guide covers the molecule-level question. For telehealth providers that combine menopause care with weight management, see our menopause brand ranking, which is a separate decision.

Key points

GLP-1 approval is based on BMI, not menopausal status.
The menopause transition shifts body composition toward more abdominal fat and less lean mass.
Tirzepatide showed the larger average trial weight loss; semaglutide is also widely used.
Muscle and bone preservation (protein, resistance training) matter more in midlife.

Molecule facts (canonical explainers)

This is a decision guide. For the plain-fact explainer of each molecule (mechanism, FDA status, dosing cautions), see:

Zepbound for women — GIP/GLP-1 receptor dual agonist (tirzepatide)
Wegovy for women — GLP-1 receptor agonist (semaglutide 2.4 mg)

Providers we review in this area

Editorial reviews only — not treatment recommendations. Prescribing decisions rest with a licensed clinician. For the full directory, see all GLP-1 for women providers.

Midi Health — Insurance-covered telehealth platform specializing in perimenopause and menopause care for women 35+.
Winona — Cash-pay menopause telehealth offering bioidentical HRT (compounded and FDA-approved). Subscription with medications shipped monthly.
Alloy Women's Health — Cash-pay menopause telehealth with FDA-approved HRT delivered monthly. Co-founded by Healthline ex-CEO.

Cost

Costs track the underlying drug — roughly $349 to $599 self-pay for tirzepatide and about $499 for semaglutide. See the Zepbound cost guide for current figures.

See the full cost breakdown in our How much does Zepbound cost?.

Frequently asked questions

Is there a GLP-1 made for menopause weight gain?: No. GLP-1 drugs are approved by BMI, not menopausal status, and no menopause-specific trial establishes a different effect. Wegovy and Zepbound are the weight-approved options a midlife woman would qualify for on the same criteria as anyone else.
Will a GLP-1 cause muscle loss in menopause?: Any large weight loss includes some lean-mass loss, and midlife women already face age-related muscle changes. Resistance training and adequate protein are commonly emphasized to help preserve muscle; discuss bone and muscle health with a clinician.
Does HRT change how a GLP-1 works?: There is no established interaction that changes GLP-1 weight effects, but combining therapies is individual. If you take or are considering hormone therapy, review the full plan with a clinician who can see both treatments together.

Sources

Every efficacy, safety, and price claim above resolves to an FDA label, published trial, guideline, or manufacturer / GoodRx pricing page. External links open in a new tab.

Keep reading

ClearHormones updates these guides as FDA status and pricing change. Verify current approval status and pricing on the manufacturer or FDA page before acting.